BDTX-1535

BDTX-1535 (EGFR-IN-76, compound 37A) is an orally active, brain-penetrant, selective and potent EGFR tyrosine kinase inhibitor. BDTX-1535 achieves potent anti-tumor activity against EGFR alterations and amplification across models including NSCLC, GBM PDX and intracranial tumors[1][2][3].

[1]Lucas MC, et al. Preparation of alkynyl quinazoline compounds as anticancer agents. World Intellectual Property Organization, WO2021030711 A1. 2021-02-18. |[2]O'Connor M, et al. Discovery of BDTX-1535, a novel 4th generation, irreversible, potent, wild type sparing EGFR MasterKey inhibitor that targets oncogenic kinase domain mutations as well as extracellular domain alterations for the treatment of NSCLC and GBM[J]. Cancer Research, 2023, 83(7_Supplement): 3396-3396.|[3]Lucas M, et al. BDTX-1535, a fourth generation EGFR inhibitor, targeting intrinsic and acquired resistance mutations in NSCLC[J]. European Journal of Cancer, 2022, 174: S22.